Table 1.

Baseline characteristics.

	Placebo (N = 2485)	SSRIs (N = 5424)	p
Female gender, No. (%)	1469 (59.1)	3234 (59.6)	0.67
Age in years, mean (SD)	45.1 (14.8)	43.9 (14.4)	0.001
Individual depressive symptoms
Affective symptoms
Depressed mood, mean (SD)	2.8 (0.6)	2.8 (0.6)	0.07
Psychic anxiety, mean (SD)	2.2 (0.7)	2.2 (0.8)	0.86
Cognitive symptoms
Feelings of guilt, mean (SD)	1.7 (0.7)	1.7 (0.7)	0.96
Suicidal thoughts, mean (SD)	1.1 (0.9)	1.1 (0.9)	0.36
Loss of interest in work/activities, mean (SD)	2.7 (0.6)	2.8 (0.6)	0.02
Retardation/concentration problems, mean (SD)	1.1 (0.8)	1.1 (0.8)	0.42
Arousal/somatic symptoms
Agitation, mean (SD)	1.1 (0.8)	1.1 (0.9)	0.41
Somatic anxiety, mean (SD)	1.6 (0.8)	1.6 (0.8)	0.34
General somatic symptom, mean (SD)	1.7 (0.5)	1.7 (0.5)	0.17
Genital symptom, mean (SD)	1.3 (0.8)	1.3 (0.8)	0.84
Hypochondriasis, mean (SD)	0.9 (0.8)	0.9 (0.8)	0.22
Gastrointestinal symptoms, mean (SD)	0.6 (0.7)	0.6 (0.7)	0.03
Loss of weight, mean (SD)	0.3 (0.6)	0.3 (0.6)	0.39
Sleep problems
Early night insomnia, mean (SD)	1.2 (0.8)	1.2 (0.8)	0.69
Middle night insomnia, mean (SD)	1.4 (0.7)	1.3 (0.8)	0.005
Early morning insomnia, mean (SD)	1.2 (0.8)	1.2 (0.8)	0.02
Insight
Lack of insight, mean (SD)	0.2 (0.4)	0.2 (0.4)	0.46